Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Stefanie Mullins, John P. Vasilakos, Katharina Deschler, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Tianhao Duan, Yang Du, Changsheng Xing, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 475
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Clément Anfray, Aldo Ummarino, Fernando Torres, et al.
Cells (2019) Vol. 9, Iss. 1, pp. 46-46
Open Access | Times Cited: 255
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 233
Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
Baharak Bahmani, Hua Gong, Brian T. Luk, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 218
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 138
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Sachin Bhagchandani, Jeremiah A. Johnson, Darrell J. Irvine
Advanced Drug Delivery Reviews (2021) Vol. 175, pp. 113803-113803
Open Access | Times Cited: 124
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Samuel I. Kim, Christopher R. Cassella, Katelyn T. Byrne
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 119
Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation
Suyog Shaha, Danika Rodrigues, Samir Mitragotri
Journal of Controlled Release (2024) Vol. 367, pp. 737-767
Closed Access | Times Cited: 20
Intratumoral Immunotherapy for Early-stage Solid Tumors
Wan Xing Hong, Sarah Haebe, Andrew S. Lee, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 13, pp. 3091-3099
Open Access | Times Cited: 136
Targeting tumor-associated macrophages as an antitumor strategy
Nan Cheng, Xuexia Bai, Yuxin Shu, et al.
Biochemical Pharmacology (2020) Vol. 183, pp. 114354-114354
Closed Access | Times Cited: 129
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
Cindy Patinote, Nour Bou Karroum, Georges Moarbess, et al.
European Journal of Medicinal Chemistry (2020) Vol. 193, pp. 112238-112238
Open Access | Times Cited: 95
Targeting Innate Immunity in Cancer Therapy
Srikrishnan Rameshbabu, Brian Labadie, Anna Argulian, et al.
Vaccines (2021) Vol. 9, Iss. 2, pp. 138-138
Open Access | Times Cited: 90
Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment
Xuan Han, Wei Qin, Yan Lv, et al.
Molecular Therapy (2021) Vol. 30, Iss. 1, pp. 327-340
Open Access | Times Cited: 86
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy
Yifan Tan, Min Wang, Yang Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 81
Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis
Fenghua Zhang, Ehab Ayaub, Bingbing Wang, et al.
EMBO Molecular Medicine (2020) Vol. 12, Iss. 8
Open Access | Times Cited: 73
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
Clément Anfray, Francesco Mainini, Elisabeth Digifico, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 9, pp. e002408-e002408
Open Access | Times Cited: 69
Deciphering albumin-directed drug delivery by imaging
Huiyu Hu, Jeremy M. Quintana, Ralph Weissleder, et al.
Advanced Drug Delivery Reviews (2022) Vol. 185, pp. 114237-114237
Open Access | Times Cited: 42
Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy
Lijia Luo, Xiang Wang, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 8, pp. 13168-13182
Open Access | Times Cited: 41
T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer
Huan-he Ni, Huanling Zhang, Lin Li, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e005151-e005151
Open Access | Times Cited: 40
Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
Cuiqing Huang, Ni Shao, Yanyu Huang, et al.
Materials Today Bio (2023) Vol. 23, pp. 100839-100839
Open Access | Times Cited: 36
Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
Samik Chakraborty, Juan Ye, Herui Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 34
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Sachin Bhagchandani, Farrukh Vohidov, Lauren E. Milling, et al.
Science Advances (2023) Vol. 9, Iss. 16
Open Access | Times Cited: 31
Tumor-associated myeloid cells in cancer immunotherapy
Xinyu Cheng, Huilan Wang, Zhongyu Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 28
The role of macrophages in the tumor microenvironment and tumor metabolism
Pritam Sadhukhan, Tanguy Y. Seiwert
Seminars in Immunopathology (2023) Vol. 45, Iss. 2, pp. 187-201
Closed Access | Times Cited: 26
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?
Chen Fu, Weiwei Tong, Lifeng Yu, et al.
Pharmacological Research (2024) Vol. 203, pp. 107160-107160
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top